Clinical Efficacy of Imdevimab/Casirivimab for Persistent Omicron SARS-CoV-2 Infection in Patients with Hematological Malignancies

Overview

Journal Intern Med

Specialty General Medicine

Date 2024 Jan 3

PMID 38171874

Authors

Masao Hagihara

Hiroyoshi Hayashi

Shiori Nakashima

Yui Imai

Hirofumi Nakano

Tomoyuki Uchida

Morihiro Inoue

Yuko Sakai-Tagawa

Mutsumi Ito

Seiya Yamayoshi

Kiyoko Iwatsuki-Horimoto

Yutaka Suzuki

Yoshihiro Kawaoka

Affiliations

Soon will be listed here.

Abstract

Objective Prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been reported in immunocompromised patients, as they poorly develop antibodies against SARS-CoV-2. We conducted a clinical trial to determine the efficacy of Imdevimab/Casirivimab (Imde/Casiri), an anti-viral monoclonal antibody (mAb), for prolonged infection at our institution. Methods Nine patients with hematological malignancies (six with malignant lymphoma and three with multiple myeloma) in our institution presented with coronavirus disease 2019 caused by SARS-CoV-2 omicron variants (one, five, and one with BA.2, BA.5, and BF.7, respectively; two undetermined). Although not all nine patients developed severe disease, viral mRNA was detected in all patients after treatment with remdesivir or molnupiravir. Imde/casiri was infused 11-49 days after the disease onset. Results Within seven days of infusion, viral RNA was undetectable in five of the nine cases. Because all seven viruses isolated from patients whose viral RNA became undetectable showed low or no sensitivity to this monoclonal antibody cocktail, the disappearance of viral RNA in these cases may not be attributable to the antibody cocktail. Conclusion It may be worth considering the use of monoclonal antibodies that show some activity against these virus variants to treat persistent SARS-CoV-2 infection in immunocompromised patients.

References

Ohara S, Fujii T, Ide S, Uchida T, Inoue M, Hagaihara M . Clinical characteristics and risk factors associated with nosocomial COVID-19 infection in patients with hematological disorders in Japan. Int J Hematol. 2021; 114(6):719-724. PMC: 8215476. DOI: 10.1007/s12185-021-03172-0. View

Bruel T, Hadjadj J, Maes P, Planas D, Seve A, Staropoli I . Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat Med. 2022; 28(6):1297-1302. DOI: 10.1038/s41591-022-01792-5. View

. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022; 399(10325):665-676. PMC: 8830904. DOI: 10.1016/S0140-6736(22)00163-5. View

Wood W, Neuberg D, Thompson J, Tallman M, Sekeres M, Sehn L . Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 2020; 4(23):5966-5975. PMC: 7724912. DOI: 10.1182/bloodadvances.2020003170. View

Fujii T, Hagihara M, Mitamura K, Nakashima S, Ohara S, Uchida T . Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan. Intern Med. 2022; 61(11):1681-1686. PMC: 9259303. DOI: 10.2169/internalmedicine.9209-21. View

Yasuda H, Tsukune Y, Watanabe N, Sugimoto K, Uchimura A, Tateyama M . Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma. Clin Lymphoma Myeloma Leuk. 2020; 20(11):774-776. PMC: 7442568. DOI: 10.1016/j.clml.2020.08.017. View

Brown L, Moran E, Goodman A, Baxendale H, Bermingham W, Buckland M . Treatment of chronic or relapsing COVID-19 in immunodeficiency. J Allergy Clin Immunol. 2021; 149(2):557-561.e1. PMC: 8585958. DOI: 10.1016/j.jaci.2021.10.031. View

Wada D, Nakamori Y, Maruyama S, Shimazu H, Saito F, Yoshiya K . Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection. Exp Hematol Oncol. 2022; 11(1):53. PMC: 9462070. DOI: 10.1186/s40164-022-00307-9. View

Shimizu A, Shirai I, Ogawa K, Miura A, Haruhara K, Oshiro K . Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies. Intern Med. 2022; 61(24):3703-3708. PMC: 9841105. DOI: 10.2169/internalmedicine.0241-22. View

10.

Shrestha L, Foster C, Rawlinson W, Tedla N, Bull R . Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. Rev Med Virol. 2022; 32(5):e2381. PMC: 9349777. DOI: 10.1002/rmv.2381. View

11.

Takashita E, Yamayoshi S, Simon V, van Bakel H, Sordillo E, Pekosz A . Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. N Engl J Med. 2022; 387(5):468-470. PMC: 9342381. DOI: 10.1056/NEJMc2207519. View

12.

Hagihara M, Imai Y, Uchida T, Ohara S, Inoue M, Sugi T . Successful Elimination of SARS-CoV-2 Following Vaccination with BNT162b2 after Prolonged Viral Infection in an Immunocompromised Lymphoma Patient. Intern Med. 2022; 61(14):2215-2219. PMC: 9381351. DOI: 10.2169/internalmedicine.9513-22. View

13.

Liu E, Lee J, Loo A, Mazur S, Sultan S, Aull M . Casirivimab-Imdevimab (REGN-COV2) for Mild to Moderate SARS-CoV-2 Infection in Kidney Transplant Recipients. Kidney Int Rep. 2021; 6(11):2900-2902. PMC: 8418987. DOI: 10.1016/j.ekir.2021.08.032. View

14.

Avanzato V, Matson M, Seifert S, Pryce R, Williamson B, Anzick S . Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell. 2020; 183(7):1901-1912.e9. PMC: 7640888. DOI: 10.1016/j.cell.2020.10.049. View

15.

Weinreich D, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R . REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. N Engl J Med. 2021; 385(23):e81. PMC: 8522800. DOI: 10.1056/NEJMoa2108163. View

16.

Razonable R, Pawlowski C, OHoro J, Arndt L, Arndt R, Bierle D . Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. EClinicalMedicine. 2021; 40:101102. PMC: 8404031. DOI: 10.1016/j.eclinm.2021.101102. View

17.

Mittelman M, Magen O, Barda N, Dagan N, Oster H, Leader A . Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting. Blood. 2021; 139(10):1439-1451. PMC: 8526123. DOI: 10.1182/blood.2021013768. View

18.

Weinreich D, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R . REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2020; 384(3):238-251. PMC: 7781102. DOI: 10.1056/NEJMoa2035002. View

19.

Mikulska M, Sepulcri C, Dentone C, Magne F, Balletto E, Baldi F . Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients. Clin Infect Dis. 2023; 77(2):280-286. DOI: 10.1093/cid/ciad181. View

20.

Wu M, Shepherd S, Fendler A, Carr E, Au L, Harvey R . Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer. Cancer Cell. 2023; 41(5):821-823. PMC: 10113515. DOI: 10.1016/j.ccell.2023.04.005. View